Tag: AT1
Atomo Diagnostics receives TGA approval to supply COVID-19 antibody test kit to Australian market
Medical device company Atomo Diagnostics (ASX: AT1) has received approval from the Therapeutic Goods Administration for its AtomoRapid (IgG/IgM) antibody test kit for patients with suspected COVID-19....
Atomo Diagnostics partners with US biotech for global marketing of COVID-19 rapid test kits
Newly-listed medical device company Atomo Diagnostics (ASX: AT1) has signed a binding agreement with US-based Access Bio Inc which will allow for the supply of Atomo’s Galileo rapid diagnostic test (R...
Atomo Diagnostics secures exclusive rights to market COVID-19 antibody test
Medical device company Atomo Diagnostics (ASX: AT1) has penned a supplementary deal with existing business partner NG Biotech that could see over 2 million additional COVID-19 antibody tests being sol...
Atomo Diagnostics secures COVID-19 test device orders ahead of ASX listing
On the eve of its ASX debut, biotech company Atomo Diagnostics (ASX: AT1) has revealed it has received additional orders for its proprietary rapid blood test devices being used to test for COVID-19.
...
Atomo Diagnostics launches $30m IPO to target global rapid diagnostic testing market
Australian medical device manufacturer Atomo Diagnostics will use a $30 million initial public offering to expand its global reach and continue development of its proprietary rapid test technologies.
...
